Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Immunogenicity of the Sanofi Pasteur's DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Hib Conjugate (Act-HIB) Monovalent Vaccine as a Three-dose Primary and Booster Vaccination in Healthy Infants in China

NCT01062477 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01062477
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01062477 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Immunogenicity of the Sanofi Pasteur's DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Hib Conjugate (Act-HIB) Monovalent Vaccine as a Three-dose Primary and Booster Vaccination in Healthy Infants in China
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2010
Completion date
December 31, 2011
Enrollment
1,056 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diphtheria, haemophilus influenzae type b, pertussis, tetanus